---
name: sci-immune-immune-repertoire-immunogenetics-workflow-301de11f
description: A reusable end-to-end workflow for map-first inventory and evolutionary mechanism discovery in antibody, B-cell, and immune receptor gene families, covering hypermutation, clonal dynamics, and isoform annotation through comparative sequence analysis and controlled validation.
scienceevolve-title: "Antibody and immune recognition · immune repertoire immunogenetics workflow"
scienceevolve-area: antibody-and-immune-recognition
---

# Purpose

Synthesize a structured, reusable route to discover and validate evolutionary and mechanistic hypotheses from immune receptor repertoires. The workflow guides agents from an initial knowledge gap through map-first sequence inventory, comparative architecture analysis, mechanism discrimination, and iterative claim refinement for antibody, B-cell, and immune receptor gene families.

# When to use

Use this workflow when:
- The target system has incomplete immunoglobulin, B-cell receptor, or immune receptor gene-family annotation.
- The goal is to infer homologous relationships, clonal dynamics, hypermutation patterns, or isoform architecture from sequence or repertoire data.
- Available evidence consists of sequence, transcript, clone, or repertoire datasets rather than functional immune-assay results alone.
- The task is to design research questions and validation strategies, not to provide clinical interpretation, therapeutic recommendations, or executable wet-lab protocols.

# Inputs required

Before starting, collect:
- Target system definition: species, lineage, tissue, cell population, developmental stage, immune state, or engineered platform.
- Repertoire data: reads, contigs, clones, transcripts, predicted proteins, or annotated receptor sequences.
- Reference sets: curated germline or receptor gene families, constant-region classes, variable-region lineages, and joining-segment references from relevant taxa or platforms.
- Comparator sets: matched controls, outgroups, unrelated sequences, and alternative-stage or alternative-disease repertoires.
- Metadata: sample provenance, sequencing strategy, annotation pipeline, batch structure, and known quality limitations.
- Constraints: ethical approvals, biosafety requirements, data governance rules, and boundaries on clinical or operational claims.

# Core Workflow

1. **Frame the knowledge gap.** Define which receptor gene class, domain, repertoire layer, or evolutionary mechanism is unknown or ambiguous, and state why it matters.
   - *Decision gate:* Stop if the gap cannot be expressed as a falsifiable comparative question.

2. **Curate inputs and audit comparability.** Document sources, accessions, data types, processing history, and metadata. Flag incompatible numbering schemes, chain definitions, immune-state labels, or annotation conventions between target and comparators.
   - *Decision gate:* Stop or harmonize if target and comparator datasets are not comparable at the required repertoire layer.

3. **Build the map-first inventory.** Annotate gene-segment usage, V(D)J recombination patterns, clonotype structure, CDR length and composition, isoform architecture, and diversity metrics. Track annotation confidence, partial assignments, and pseudogene ambiguity.
   - *Iteration:* If annotation completeness is low, refine references or filtering rules and re-inventory before proceeding.

4. **Formulate mechanism-linked hypotheses.** Generate ranked hypotheses that link observed repertoire patterns to candidate mechanisms:
   - germline constraint or recombination bias;
   - somatic hypermutation or affinity maturation;
   - clonal expansion or selection;
   - developmental-stage or state-specific dynamics;
   - technical bias from sampling, primers, or annotation.
   - For each hypothesis, record evidence strength, key assumptions, and likely failure modes.
   - *Decision gate:* Require at least one strong contrast that can discriminate generation from selection before advancing.

5. **Design controlled comparisons.** Define variables, contrast groups, and controls:
   - Positive, negative, outgroup, and technical controls.
   - Biological comparators matched for confounders.
   - Predefined evaluation metrics and acceptance criteria.
   - Stopping conditions for low quality, ambiguous assignment, or failed controls.

6. **Execute comparative analysis.** Perform homology search, multiple alignment, domain-architecture comparison, phylogenetic placement, mutation-spectrum profiling, and clonal-dynamics analysis. Compare observed distributions against expected or baseline distributions and null models.

7. **Evaluate control behavior and robustness.** Confirm that controls behave as expected. Repeat key comparisons under alternative references, alignment settings, annotation tools, or model assumptions. Test whether the pattern persists after adjusting for sampling depth, batch, clonal expansion, and redundancy.
   - *Decision gate:* If negative controls show apparent homology, if the signal disappears under sensitivity analysis, or if contamination cannot be ruled out, stop mechanistic claims and investigate artifacts.

8. **Assign evidence levels and bound claims.** Label each finding as confirmed, likely, ambiguous, unlikely, or unsupported. Restrict conclusions to the specific system, condition, and dataset. Distinguish sequence-level annotation from functional or clinical mechanism.

9. **Iterate or redesign.** Use results to update hypotheses:
   - If evidence is strong and controls pass, broaden the question cautiously.
   - If evidence is moderate, refine references, expand outgroups, or seek independent sequence support.
   - If evidence is weak or controls fail, reclassify findings as provisional, stop downstream engineering or clinical claims, and redesign the minimal validation.
   - *Stop condition:* Terminate if germline annotation is too incomplete, sampling depth is systematically biased, or the feature vanishes under alternative analysis choices.

10. **Plan orthogonal validation and next-cycle questions.** Identify the smallest independent dataset, structural readout, binding assay, or cross-cohort comparison that could strengthen or refute the leading hypothesis. Frame specific follow-up questions.

# Output Format

Return the following structured deliverables:
1. **Research question and gap statement:** the specific annotation or mechanism question and why it is unresolved.
2. **Map-first inventory summary:** annotated repertoire layers, confidence levels, and known gaps.
3. **Hypothesis table:** each hypothesis with evidence strength, proposed mechanism, key assumptions, minimal validation path, and likely failure modes.
4. **Controlled design plan:** contrast groups, variables, controls, metrics, acceptance criteria, and stopping conditions.
5. **Analysis record:** curation rules, annotation methods, comparative analyses, robustness checks, and control outcomes.
6. **Evidence-level assignment:** confirmed, likely, ambiguous, unlikely, or unsupported labels for each claim.
7. **Iteration plan:** how results update hypotheses and what the next validation step should be.
8. **Boundary statement:** scope of validity, excluded interpretations, and residual uncertainty.

# Validation Gates

- **Provenance gate:** All data sources, references, and processing steps are documented and reproducible.
- **Comparability gate:** Chain definitions, numbering conventions, immune-state metadata, and annotation methods are compatible across target and comparators.
- **Annotation gate:** Gene-segment and CDR assignments meet minimum confidence thresholds; ambiguous or partial annotations are flagged.
- **Control gate:** Positive, negative, outgroup, and technical controls are defined and behave as expected before interpreting target patterns.
- **Robustness gate:** Key conclusions are stable under alternative references, alignment settings, annotation tools, and filtering rules.
- **Statistical gate:** Multiple testing, effect sizes, uncertainty intervals, and nonindependence of clonotypes are addressed.
- **Boundary gate:** Claims are scoped to the specific species, tissue, developmental stage, immune state, and dataset.

# Claim Boundaries

- Sequence homology and gene-family annotation are supported by conserved-domain evidence and comparative alignment, but subclass or lineage assignment remains provisional without independent validation.
- Repertoire patterns such as gene usage skew or CDR architecture differences are descriptive; mechanistic interpretations (selection, hypermutation targeting, clonal expansion) require orthogonal evidence.
- Findings from a single cohort, species, or dataset are not treated as field-wide consensus.
- Sequence-level discoveries do not imply functional binding, therapeutic utility, or clinical relevance without separate validation.
- The workflow does not authorize clinical diagnosis, treatment recommendations, or executable laboratory protocols.

# Failure Modes

- **Contamination or source mislabeling:** candidate sequences do not match the intended sample.
- **Paralogy and family similarity:** shared domain architecture is mistaken for one-to-one orthology.
- **Database bias:** overrepresented reference taxa distort assignment or phylogenetic placement.
- **Single-sequence overinterpretation:** a single low-quality or unconfirmed candidate drives a claim.
- **Assembly or chimera artifacts:** unusual domain order or conflicting read support indicates a spurious sequence.
- **Low-complexity similarity:** matches driven by repetitive or non-diagnostic regions.
- **Sampling and amplification bias:** uneven depth, primer mismatch, or batch effects create apparent repertoire differences.
- **Annotation artifact:** CDR boundary definitions, germline reference choice, or clonotype clustering thresholds determine the observed pattern.
- **Confounding by population mixing:** unseparated cell states or developmental stages obscure state-specific signals.
- **Overfitting:** rare motifs or clone-specific features are generalized without recurrence or independent support.

# Validity Checks

- **Confounding:** Assess donor heterogeneity, developmental stage, tissue source, cell-sorting purity, isotype, batch, sequencing depth, and amplification bias.
- **Annotation validity:** Verify germline reference completeness, CDR boundary robustness, and consistency of V(D)J assignment across tools.
- **Statistical validity:** Report effect sizes and uncertainty, correct for multiple comparisons, and avoid causal claims from enrichment alone.
- **Reproducibility:** Document metadata, filtering rules, code, and parameter choices so the workflow can be repeated.
- **Mechanistic specificity:** Distinguish recombination, mutation, expansion, selection, survival, and technical bias.
- **Replication:** Require independent samples, orthogonal assays, or cross-cohort consistency before strong claims.
- **Boundary conditions:** State which taxa, platforms, developmental stages, and sequence types the conclusions can and cannot support.
- **Rare-event validity:** Insist on recurrence and independent evidence for rare genes, motifs, or clonotypes.

# Provenance

- Derived from cluster 75, subcluster 75.0.split0.
- Synthesized from source skills: comparative-immunoglobulin-sequence-discovery, autoantibody-repertoire-exploration, cutaneous-bcell-repertoire-exploration, immunoglobulin-repertoire-architecture-discovery, tlr-driven-b-cell-repertoire-exploration, immunoglobulin-diversification-exploration, repertoire-mining-research-discovery, autoimmune-antibody-research-pattern.
